Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of Gemcitabine Plus Z-360 in Metastatic Pancreatic Adenocarcinoma Compared With Gemcitabine Plus Placebo ( ZIPANG Study )

NCT02117258 is registered in ClinicalTrials.gov with Zeria Pharmaceutical as lead sponsor.

NCT NCT02117258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02117258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of Gemcitabine Plus Z-360 in Metastatic Pancreatic Adenocarcinoma Compared With Gemcitabine Plus Placebo ( ZIPANG Study )
Lead sponsor
Zeria Pharmaceutical
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2014
Completion date
March 31, 2017
Enrollment
167 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma